NCT01444742View on ClinicalTrials.gov

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 16, 2011

Primary Completion Date

January 29, 2017

Study Completion Date

January 29, 2017

Conditions
LeukemiaMyeloproliferative Diseases
Interventions
DRUG

Clofarabine

"Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)"

DRUG

Cytarabine

"Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)"

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01444742 - Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter